Take-home message: Use of a home monitoring device to monitor patients at high risk for wet age-related macular degeneration may have a considerable public health impact over time.
Philadelphia—Early identification of individuals at risk of developing neovascular age-related macular degeneration (AMD) is key to preventing and minimizing vision loss from the disease, urged Carl Regillo, MD.
Thanks to use of a home monitoring device (ForeseeHome AMD Monitor with Preferential Hyperacuity Perimetry, Notal Vision), monitoring patients at high risk for wet AMD may have a substantial public health impact over time, with more patients able to maintain functional vision as a result of early intervention and treatment in the disease process, said Dr. Regillo, chief, Wills Eye Hospital Retina Service, and professor of ophthalmology, Thomas Jefferson University, Philadelphia.
AREDS2-HOME Study Group
In the Age-Related Eye Disease Study 2 (AREDS2) HOme Monitoring of the Eye (HOME) study, AREDS data were used to identify the U.S. population at risk, apply the HOME study findings with the device and known epidemiologic data to the target population, and estimate the potential public health effect of home monitoring with the device.